Absence of HER2 overexpression in metastatic malignant melanoma
- 16 September 2003
- journal article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 84 (2) , 82-88
- https://doi.org/10.1002/jso.10297
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A reviewGene, 1995
- Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.Journal of Clinical Oncology, 1993
- Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sexCancer, 1993
- MDR-1 Expression in Metastatic Malignant MelanomaJournal of Surgical Research, 1993
- Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.Journal of Clinical Oncology, 1992
- The long term prognostic significance of c-erbB-2 in primary breast cancerBritish Journal of Cancer, 1991
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.Journal of Clinical Oncology, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987